Insider Buying: OptimizeRx Co. (NASDAQ:OPRX) CEO Acquires 20,000 Shares of Stock

OptimizeRx Co. (NASDAQ:OPRX) CEO William J. Febbo bought 20,000 shares of OptimizeRx stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

OptimizeRx Stock Performance

OptimizeRx stock opened at $5.23 on Wednesday. The company has a market cap of $96.34 million, a PE ratio of -3.93 and a beta of 1.34. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx Co. has a 1 year low of $3.78 and a 1 year high of $16.65. The company’s 50-day moving average is $5.48 and its two-hundred day moving average is $7.92.

Hedge Funds Weigh In On OptimizeRx

Several large investors have recently bought and sold shares of OPRX. Summit Securities Group LLC acquired a new stake in OptimizeRx during the 2nd quarter worth $25,000. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 189.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Quest Partners LLC grew its stake in shares of OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock worth $76,000 after purchasing an additional 9,739 shares during the period. Connors Investor Services Inc. grew its stake in shares of OptimizeRx by 15.1% during the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after purchasing an additional 2,500 shares during the period. Finally, Barclays PLC increased its holdings in OptimizeRx by 358.5% in the third quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after purchasing an additional 21,060 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on OPRX shares. Barclays cut their price objective on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, November 14th. Royal Bank of Canada reduced their price target on shares of OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, November 14th. Stifel Nicolaus lowered their price objective on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. JMP Securities dropped their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday, November 14th. Finally, Roth Mkm reissued a “buy” rating and set a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average price target of $10.42.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.